Leiras offers drug delivery technology:
This article was originally published in Clinica
Executive Summary
Finnish company Leiras is to offer to biotechnology and pharmaceutical companies its proprietary polymer-based drug delivery technology, known as Delvivo. The company, which is part of the German group Schering, says its technology enables active drug ingredients to be released over a long time and at an even rate into the body. There is also the possibility that Leiras would market some products emerging from any deals. The technology is also the basis of Schering's intrauterine system, Mirena, which is sold in 48 countries worldwide, including the US.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.